Cresco Labs Provides Update on Texas License Previously Awarded by Texas Department of Public Safety

The most recent news, dated May 11 2026, announces that the Texas Department of Public Safety (DPS) has rescinded the conditional medical cannabis license previously awarded to Cresco Labs Texas, LLC. The change follows a retroactive correction to the DPS’s tabulation methodology, which impacted multiple applicants. As a result, Cresco has been moved to the Texas Compassionate Use Program (TCUP) eligibility list. The company remains eligible to receive a conditional license only if one of the 12 currently selected licensees fails to meet due diligence or operationalization requirements within 24 months. Cresco states it is evaluating options to protect its application’s original determination and stands ready to deploy resources if permitted.

This development is a clear negative surprise that materially weakens the near‑term growth narrative.
- On April 2 2026, Cresco announced it had been conditionally awarded a vertically integrated Texas license – a significant positive catalyst, as Texas represents a population of ~30 million and a large potential medical market. The stock rallied on the news.
- Only days before the rescission, the Q1 2026 earnings release (May 8) highlighted the Texas conditional award as a key accomplishment and growth driver.
- The loss of the conditional license removes a concrete, tangible expansion opportunity that had just been factored into market expectations. Now the company merely sits on a waiting list, with no guarantee that a license will ever materialize. While the possibility remains if one of the chosen licensees falters, the path is highly uncertain and dependent on third‑party failures.
The news directly undercuts the positive momentum generated by the federal rescheduling to Schedule III and the company’s own operational progress. Market reaction is likely to be sharply negative, as the Texas license was a key part of the bull case.

Cresco Labs is a vertically integrated multi‑state cannabis operator with a presence in several key U.S. medical and adult‑use markets. Its brand portfolio includes Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s, and Remedi, sold through the Sunnyside dispensary network. The flagship growth project had become the Texas medical license, which would have granted vertically integrated rights in a massive untapped patient population. Other recent expansion highlights include new dispensaries in Ohio, a management services agreement in Pennsylvania, the first harvest in Kentucky, and a branded flower launch in Germany.